Table 3.
Open in new tab

Univariate and multivariate linear regression analysis of predictors of DIAPS change during follow-up

Beta coeff (95% CI)P-value
Univariate Analysis
 aGAPSS0.04 (0.02, 0.05)<0.001
 Gender (female)–0.13 (–0.32, 0.06)0.188
 Age at diagnosis–0.008 (–0.015, –0.001)0.017
 Disease duration0.001 (0.00001, 0.002)0.047
 Active smoking0.33 (–0.59, 1.27)0.482
 Oral contraceptives–0.21 (–0.50, 0.081)0.156
 Congenital thrombophiliasa–0.3 (–0.81, 0.21)0.243
 Arterial hypertension0.35 (0.17, 0.53)<0.001
 Dyslipidaemia0.17 (–0.17, 0.36)0.075
 Presence of SLE0.31 (0.09, 0.52)0.005
 aCL0.09 (–0.12, 0.30)0.408
 aβ2GPI0.22 (0.05, 0.40)0.013
 LAC0.27 (0.08, 0.46)0.005
 Double positivityb0.23 (0.05, 0.42)0.011
 Triple positivity0.22 (0.03, 0.40)0.024
 LDA0.01 (–0.17, 0.20)0.902
 VKA0.13 (–0.04, 0.33)0.139
 HCQ0.26 (0.06, 0.47)0.012
Multivariate Analysisc
 aGAPSS0.037 (0.020, 0.055)<0.001
 Age at diagnosis–0.005 (–0.012, 0.002)0.168
 Disease duration0.0005 (–0.0005, 0.001)0.307
 Presence of SLE0.155 (–0.095, 0.406)0.222
 Congenital Thrombophilias–0.27 (–0.734, 0.188)0.245
 HCQ0.094 (–0.141, 0.329)0.432
Beta coeff (95% CI)P-value
Univariate Analysis
 aGAPSS0.04 (0.02, 0.05)<0.001
 Gender (female)–0.13 (–0.32, 0.06)0.188
 Age at diagnosis–0.008 (–0.015, –0.001)0.017
 Disease duration0.001 (0.00001, 0.002)0.047
 Active smoking0.33 (–0.59, 1.27)0.482
 Oral contraceptives–0.21 (–0.50, 0.081)0.156
 Congenital thrombophiliasa–0.3 (–0.81, 0.21)0.243
 Arterial hypertension0.35 (0.17, 0.53)<0.001
 Dyslipidaemia0.17 (–0.17, 0.36)0.075
 Presence of SLE0.31 (0.09, 0.52)0.005
 aCL0.09 (–0.12, 0.30)0.408
 aβ2GPI0.22 (0.05, 0.40)0.013
 LAC0.27 (0.08, 0.46)0.005
 Double positivityb0.23 (0.05, 0.42)0.011
 Triple positivity0.22 (0.03, 0.40)0.024
 LDA0.01 (–0.17, 0.20)0.902
 VKA0.13 (–0.04, 0.33)0.139
 HCQ0.26 (0.06, 0.47)0.012
Multivariate Analysisc
 aGAPSS0.037 (0.020, 0.055)<0.001
 Age at diagnosis–0.005 (–0.012, 0.002)0.168
 Disease duration0.0005 (–0.0005, 0.001)0.307
 Presence of SLE0.155 (–0.095, 0.406)0.222
 Congenital Thrombophilias–0.27 (–0.734, 0.188)0.245
 HCQ0.094 (–0.141, 0.329)0.432
a

Congenital thrombophilias include factor V Leiden mutation (n = 1) and prothrombin G20210A mutation (n = 6).

b

Any combination of two positive aPL tests based on the laboratory criteria of the Updated Sapporo APS Classification Criteria.

c

Adjusted for age at diagnosis, disease duration, and presence of SLE.

aβ2GPI: anti-β2-glycoprotein I antibodies; aCL: anticardiolipin antibodies; aGAPSS: adjusted global APS score LAC: lupus anticoagulant; LDA: low dose aspirin; VKA: vitamin K antagonists.

Table 3.
Open in new tab

Univariate and multivariate linear regression analysis of predictors of DIAPS change during follow-up

Beta coeff (95% CI)P-value
Univariate Analysis
 aGAPSS0.04 (0.02, 0.05)<0.001
 Gender (female)–0.13 (–0.32, 0.06)0.188
 Age at diagnosis–0.008 (–0.015, –0.001)0.017
 Disease duration0.001 (0.00001, 0.002)0.047
 Active smoking0.33 (–0.59, 1.27)0.482
 Oral contraceptives–0.21 (–0.50, 0.081)0.156
 Congenital thrombophiliasa–0.3 (–0.81, 0.21)0.243
 Arterial hypertension0.35 (0.17, 0.53)<0.001
 Dyslipidaemia0.17 (–0.17, 0.36)0.075
 Presence of SLE0.31 (0.09, 0.52)0.005
 aCL0.09 (–0.12, 0.30)0.408
 aβ2GPI0.22 (0.05, 0.40)0.013
 LAC0.27 (0.08, 0.46)0.005
 Double positivityb0.23 (0.05, 0.42)0.011
 Triple positivity0.22 (0.03, 0.40)0.024
 LDA0.01 (–0.17, 0.20)0.902
 VKA0.13 (–0.04, 0.33)0.139
 HCQ0.26 (0.06, 0.47)0.012
Multivariate Analysisc
 aGAPSS0.037 (0.020, 0.055)<0.001
 Age at diagnosis–0.005 (–0.012, 0.002)0.168
 Disease duration0.0005 (–0.0005, 0.001)0.307
 Presence of SLE0.155 (–0.095, 0.406)0.222
 Congenital Thrombophilias–0.27 (–0.734, 0.188)0.245
 HCQ0.094 (–0.141, 0.329)0.432
Beta coeff (95% CI)P-value
Univariate Analysis
 aGAPSS0.04 (0.02, 0.05)<0.001
 Gender (female)–0.13 (–0.32, 0.06)0.188
 Age at diagnosis–0.008 (–0.015, –0.001)0.017
 Disease duration0.001 (0.00001, 0.002)0.047
 Active smoking0.33 (–0.59, 1.27)0.482
 Oral contraceptives–0.21 (–0.50, 0.081)0.156
 Congenital thrombophiliasa–0.3 (–0.81, 0.21)0.243
 Arterial hypertension0.35 (0.17, 0.53)<0.001
 Dyslipidaemia0.17 (–0.17, 0.36)0.075
 Presence of SLE0.31 (0.09, 0.52)0.005
 aCL0.09 (–0.12, 0.30)0.408
 aβ2GPI0.22 (0.05, 0.40)0.013
 LAC0.27 (0.08, 0.46)0.005
 Double positivityb0.23 (0.05, 0.42)0.011
 Triple positivity0.22 (0.03, 0.40)0.024
 LDA0.01 (–0.17, 0.20)0.902
 VKA0.13 (–0.04, 0.33)0.139
 HCQ0.26 (0.06, 0.47)0.012
Multivariate Analysisc
 aGAPSS0.037 (0.020, 0.055)<0.001
 Age at diagnosis–0.005 (–0.012, 0.002)0.168
 Disease duration0.0005 (–0.0005, 0.001)0.307
 Presence of SLE0.155 (–0.095, 0.406)0.222
 Congenital Thrombophilias–0.27 (–0.734, 0.188)0.245
 HCQ0.094 (–0.141, 0.329)0.432
a

Congenital thrombophilias include factor V Leiden mutation (n = 1) and prothrombin G20210A mutation (n = 6).

b

Any combination of two positive aPL tests based on the laboratory criteria of the Updated Sapporo APS Classification Criteria.

c

Adjusted for age at diagnosis, disease duration, and presence of SLE.

aβ2GPI: anti-β2-glycoprotein I antibodies; aCL: anticardiolipin antibodies; aGAPSS: adjusted global APS score LAC: lupus anticoagulant; LDA: low dose aspirin; VKA: vitamin K antagonists.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close